Peptide Comparison
MK-677 vs Sermorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
MK-677 has stronger documented evidence (Phase 3 (not approved)) than Sermorelin (Discontinued (FDA approval 1990; US withdrawal 2008)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. Sermorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| MK-677 | Sermorelin | |
|---|---|---|
| Class | Oral non-peptide ghrelin receptor agonist | GHRH analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine | Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release |
| Route | Oral | SC injection |
| Half-life | ~24 hrs | ~10-20 min |
| Dosage (research) | 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) | 200-500 mcg SC at bedtime daily |
| Evidence tier | Phase 3 (not approved) | Discontinued (FDA approval 1990; US withdrawal 2008) |
| Research depth | 120 indexed | 149 indexed |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) | Injection site reactions; headache; flushing |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick MK-677 or Sermorelin?
MK-677 has stronger documented evidence (Phase 3 (not approved)) than Sermorelin (Discontinued (FDA approval 1990; US withdrawal 2008)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. Sermorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between MK-677 and Sermorelin?
MK-677 is classed as Oral non-peptide ghrelin receptor agonist; Sermorelin is classed as GHRH analog. Reported mechanism: MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: MK-677, ~24 hrs; Sermorelin, ~10-20 min. Routes in published studies: MK-677, Oral; Sermorelin, SC injection.
Which has stronger evidence, MK-677 or Sermorelin?
MK-677 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 120 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies.
Which is more accessible, MK-677 or Sermorelin?
Neither MK-677 nor Sermorelin is an FDA-approved drug. Catalog status: MK-677, Research Chemical; Sermorelin, Compounding Restricted. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022).
Are MK-677 and Sermorelin ever combined?
MK-677 and Sermorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…